SRSuresh Mahendra Raj

Suresh Mahendra Raj

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suresh Mahendra Raj has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Abrar Ahmad Chughtai

    School of Public Health and Community Medicine, Faculty of Medicine, University of New South Wales, Samuels Building, Sydney, NSW 2052, Australia

    1 shared publication
  • Anurag Sharma

    Centre for Health Economics, Monash University, Melbourne, Australia

    1 shared publication
  • C. Raina MacIntyre

    Biosecurity Program, The Kirby Institute, Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia; College of Public Affairs and Community Solutions, Arizona State University, Phoenix, AZ 85004, USA

    1 shared publication
  • Joyce Yu

    University of Sydney Camperdown NSW Australia

    1 shared publication
  • Timothy C. Tan

    Faculty of Medicine, University of New South Wales, Sydney, NSW 2052, Australia; Department of Cardiology, Blacktown Hospital, Blacktown, NSW 2148, Australia; School of Medicine, Western Sydney University, Sydney, NSW 2751, Australia; Faculty of Medicine and Health, University of Sydney, Sydney, NSW 2006, Australia

    1 shared publication

Latest Publications

  • Cost-benefit analysis of a national influenza vaccination program in preventing hospitalisation costs in Australian adults aged 50–64 years old

    by Suresh Mahendra Raj, Abrar Ahmad Chughtai, Anurag Sharma, Timothy C. Tan, C. Raina MacIntyre


  • Open Access

    Efficacy of three key antiviral drugs used to treat orthopoxvirus infections: a systematic review

    by Joyce Yu, Suresh Mahendra Raj

    Background: In a global political climate increasingly concerned about terrorism, bioterrorism agents such as smallpox would undoubtedly be catastrophic. Since WHO announced the eradication of smallpox in 1980, consequently discontinuing the worldwide vaccination campaign, today's population is either immunologically naïve or has waning levels of protection. Further, up to 25% of today's population are contraindicated for smallpox vaccination due to various immunodeficiency conditions. The aim of this study was to evaluate the efficacy of the anti-DNA antivirals cidofovir (CDV), brincidofovir (BCV) and tecovirimat against smallpox and other orthopoxviruses. As of July 2018, FDA approved tecovirimat as the first treatment for smallpox. Methods: A systematic review was conducted to identify relevant literature describing the efficacy and safety of CDV, BCV and tecovirimat including in vitro and in vivo animal studies, human safety trials and human case reports of orthopoxvirus infection. Results: 158 studies met the inclusion criteria. In vitro and in vivo animal studies have found that CDV, BCV and tecovirimat are highly efficacious when used therapeutically and prophylactically. They are partially protective in moderate, but not severe, immunodeficiency models. Clinical trials consistently report BCV and tecovirimat to be safe and well tolerated in humans. In human case reports, CDV, BCV and tecovirimat contributed to recovery from orthopoxvirus infection. BCV and tecovirimat demonstrate strong synergistic effect and may reduce risk of antiviralresistant strains. Conclusion: BCV and tecovirimat are particularly promising as anti-smallpox agents. Gaps in the literature indicate that further research should focus on developing more robust immunodeficiency and antiviral-resistance models.